These findings not only provide a scientific basis for the clinical use of THSWD in CHD, but also offer novel targets (e.g., STAT1) and compounds (e.g., 6-Hydroxynaringenin) for future drug development. The gene discussed is STAT1; the disease is coronary artery disorder.